William Levine, DDS, is founder and chief scientific officer of Israel-based CannRx.

Q: What is CannRx’s niche in the marketplace?

A: We’re actually a subdivision of Izun pharmaceuticals, which has been involved in botanical medicine over the past 20 years. What we do is we want to be able to create a better botanical product from a therapeutic standpoint, as well as a safety standpoint. We don’t grow cannabis and we don’t sell cannabis products, but we do work with partners who do. We are technology developers — our role is to take the cannabis you grow and make it much better.

Q: What’s one of the greatest challenges for physicians and patients with respect to cannabis-derived medicine?

A: Making sure that the product you are providing to the consumer/patient is therapeutically active, consistent and safe. Right now our industry is falling short.

Q: What is CannTrap? How does it address this?

A: What CannTrap does is it’s a protein-binding system where we create nanoparticles holding cannabinoids and terpenes and improve the bioavailability (the ability of the body to intake a chemical). The average bioavailability with cannabis is around 10 percent, but we’re seeing a bioavailability of 50 to 60 percent with CannTrap, with an onset of between five minutes to 30 minutes. It’s basically a platform where you can use either a single cannabinoid like THC or a full spectrum extract. Any one of those can be used with the CannTrap system to get you more consistent and controllable outcomes.

Q: How does this benefit patients? Physicians?

A: If a patient is taking cannabis for pain, the less time you have to wait the happier you are. This can be in your system in 15 minutes rather than one or two hours. It’s a much more efficient way of taking in medicine. We’re giving the doctors the comfort that this is a delivery system they should be using.

Q: Is CannTrap in any products yet?

A: We’ve been in stealth mode prior to putting out our press release. We are now beginning to enter into discussions with various companies and partners about this.

View article